Coronary artery disease as a risk factor for metabolic dysfunction-associated steatotic liver disease and liver fibrosis

被引:0
|
作者
Vega, Luis [1 ]
Simian, Daniela [1 ]
Gajardo, Abraham I. [2 ]
Salinas, Marcelo [1 ]
Urra, Andrea [1 ]
Cattaneo, Maximo [1 ]
Pino, Rosario [1 ]
Roblero, Juan P. [1 ]
Urzua, Alvaro [1 ]
Rojas, Katherine [1 ]
Poniachik, Jaime [1 ]
机构
[1] Hosp Clin Univ Chile, Med Dept, Gastroenterol Sect, Santiago, Chile
[2] Hosp Clin Univ Chile, Med Dept, Crit Patient Care Unit, Santiago, Chile
关键词
Metabolic dysfunction-associated fatty liver disease; Liver fibrosis; Coronary heart disease;
D O I
10.1016/j.aohep.2024.101511
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Introduction and Objectives: Patients with metabolic dysfunction-associated steatotic liver disease (MASLD) are at an increased cardiovascular risk. On the contrary, non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients with coronary heart disease (CHD). However, it is not known whether patients with significant CHD show a higher frequency of liver fibrosis. This study aimed to determine the frequency of MASLD and liver fibrosis in patients with CHD and to assess whether coronary stenosis is significantly associated with MASLD and fibrosis. Patients and Methods: This observational and analytical study included adult patients without any known liver disease who underwent coronary angiography for suspected coronary artery disease (Jul 2021-Jul 2022). The presence of significant CHD (> 50% stenosis of at least one coronary artery) was determined. Liver elastography (FibroScan (R)) was performed up to 6 months after the coronary angiographic study to determine liver fibrosis, a measurement of liver stiffness (> 6.5 Kpa). Fisher's test, Mann-Whitney U test, and logistic regression models were used (p < 0.05). Results: The study included 113 patients (76% men, average age: 63 years [standard deviation: 9.9]), of which 72% presented with significant CHD. The prevalence rate of MASLD was 52%. Liver fibrosis was present in 12% of the patients and all patients in the significant CHD group (p = 0.007). An increase in the number of vessels with significant CHD increased the probability of liver fibrosis (odds ratio, 1.79; 95% confidence interval, 1.06-3.04; p = 0.029). Conclusions: MASLD is highly prevalent in patients with significant CHD but without known liver damage. These data suggest that MASLD and liver fibrosis should be investigated in patients with CHD. The presence of confounding variables, especially the presence of type 2 diabetes mellitus, should be evaluated in further studies. (c) 2024 Published by Elsevier Espa & ntilde;a, S.L.U. on behalf of Fundaci & oacute;n Cl & iacute;nica M & eacute;dica Sur, A.C. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
引用
收藏
页数:5
相关论文
共 50 条
  • [21] Update in lean metabolic dysfunction-associated steatotic liver disease
    Sato-Espinoza, Karina
    Chotiprasidhi, Perapa
    Huaman, Mariella R.
    Diaz-Ferrer, Javier
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (03)
  • [22] Metabolic dysfunction-associated steatotic liver disease: A silent pandemic
    Samanta, Arghya
    Sen Sarma, Moinak
    [J]. WORLD JOURNAL OF HEPATOLOGY, 2024, 16 (04)
  • [23] Role of Glucocorticoids in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Polyzos, Stergios A.
    Targher, Giovanni
    [J]. CURRENT OBESITY REPORTS, 2024, 13 (02) : 242 - 255
  • [24] Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease
    Mellemkjaer, Anders
    Kjaer, Mikkel Breinholt
    Haldrup, David
    Gronbaek, Henning
    Thomsen, Karen Louise
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 122 : 28 - 34
  • [25] Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Rodriguez, Luis A.
    Schmittdiel, Julie A.
    Liu, Liyan
    Macdonald, Brock A.
    Balasubramanian, Sreepriya
    Chai, Krisna P.
    Seo, Suk I.
    Mukhtar, Nizar
    Levin, Theodore R.
    Saxena, Varun
    [J]. JAMA NETWORK OPEN, 2024, 7 (07)
  • [26] Comparing imaging modalities in the assessment of fibrosis in metabolic dysfunction-associated steatotic liver disease
    Ravanbakhsh, Naseem
    Browne, Debra
    Weaver, Carly
    Gholikhani, Asal
    Kavarian, Patil
    Mitsinikos, Tania
    [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2024,
  • [27] Natural history of metabolic dysfunction-associated steatotic liver disease
    Lekakis, Vasileios
    Papatheodoridis, George, V
    [J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2024, 122 : 3 - 10
  • [28] Mechanism of PANoptosis in metabolic dysfunction-associated steatotic liver disease
    Ni, Keying
    Meng, Lina
    [J]. CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2024, 48 (07)
  • [29] Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease
    Lu, Chuan
    Chen, Yan
    Zhang, Yue
    Zhao, Xin
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY, 2023, 16 : 2627 - 2637
  • [30] Different Associations of Coffee Consumption with the Risk of Incident Metabolic Dysfunction-Associated Steatotic Liver Disease and Advanced Liver Fibrosis
    Lee, Jun-Hyuk
    Park, Jooyong
    Ahn, Sang Bong
    [J]. NUTRIENTS, 2024, 16 (01)